Apellis Pharmaceuticals Inc Earnings

Apellis Pharmaceuticals Inc’s revenue jumped 98.45% since last year same period to $196.83Mn in the Q3 2024. On a quarterly growth basis, Apellis Pharmaceuticals Inc has generated -1.43% fall in its revenue since last 3-months.

Apellis Pharmaceuticals Inc’s net profit jumped 59.04% since last year same period to $-57.45Mn in the Q3 2024. On a quarterly growth basis, Apellis Pharmaceuticals Inc has generated -52.55% fall in its net profits since last 3-months.

Apellis Pharmaceuticals Inc’s net profit margin jumped 79.36% since last year same period to -29.19% in the Q3 2024. On a quarterly growth basis, Apellis Pharmaceuticals Inc has generated -54.76% fall in its net profit margins since last 3-months.

Apellis Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.54 - a -34.36% fall from last quarter’s estimates.

Apellis Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.54.

Apellis Pharmaceuticals Inc’s earning per share (EPS) jumped 60.27% since last year same period to -0.29 in the Q4 2024. This indicates that the Apellis Pharmaceuticals Inc has generated 60.27% annual rate of jump in its earning per share (EPS) in the last 4 quarters.